| |
BMI ≥ 30
|
BMI < 30
|
|---|
| |
Bradykinin response [10-8M] -% dilation (Std. Error)
|
Bradykinin response [10-8M] -% dilation (Std. Error)
|
|---|
| |
(+) Drug
|
(-) Drug
|
P Value
|
(+) Drug
|
(-) Drug
|
P Value
|
|---|
|
ACE inhibitor
|
63.5 (9.5)
|
51.0 (5.3)
|
0.237
|
33.5 (6.2)
|
58.2 (5.8)
|
0.007
|
|
Angiotensin receptor blocker
|
55.1 (6.1)
|
54.1 (7.2)
|
0.919
|
64.4 (8.1)
|
36.9 (5.1)
|
0.007
|
|
Aspirin
|
57.1 (4.8)
|
43.1 (14.6)
|
0.261
|
49.2 (5.3)
|
30.5 (9.2)
|
0.086
|
|
Statin
|
58.3 (4.7)
|
50.4 (8.6)
|
0.412
|
53.7 (5.1)
|
20.1 (6.0)
|
0.001
|
|
Insulin
|
48.3 (7.6)
|
56.3 (5.6)
|
0.492
|
57.9 (10.3)
|
41.3 (5.2)
|
0.165
|
|
Anti-diabetics
|
62.0 (23.0)
|
52.6 (5.1)
|
0.424
|
46.2 (11.5)
|
44.1 (5.3)
|
0.867
|
|
Beta blocker
|
89.3% of obese patients are on beta blockers; test not valid
|
51.5 (5.7)
|
34.8 (7.6)
|
0.081
|
|
Diuretic
|
50.3 (9.8)
|
55.8 (5.4)
|
0.641
|
52.3 (6.0)
|
38.9 (6.7)
|
0.166
|
|
Calcium channel blocker
|
55.8 (7.6)
|
53.5 (6.1)
|
0.811
|
38.6 (7.2)
|
49.2 (6.2)
|
0.267
|
|
H+ blocker
|
62.0 (6.8)
|
49.8 (62.6)
|
0.210
|
45.8 (7.9)
|
44.3 (5.5)
|
0.907
|
|
Nitrate
|
59.9 (8.6)
|
52.5 (5.7)
|
0.487
|
11.1% of non-obese patients are on nitrates; test not valid
|
- BMI – body mass index; ACE – angiotensin converting enzyme; ARB – angiotensin receptor blocker; CCB – calcium channel blocker, Significance determined by 1-Way ANOVA. Data is presented as the mean ± standard deviation.
